Cachexia is a complex wasting syndrome that causes severe weight and muscle loss in people living with serious chronic diseases, particularly cancer. While it affects millions worldwide and contributes significantly to illness and mortality, targeted treatments are emerging that offer hope for better management and improved quality of life.

How Treatment Approaches Aim to Restore Health and Function

The goal of treating cachexia is not simply to help patients gain weight, but to address a complex set of interconnected problems that affect the entire body. Treatment focuses on slowing or reversing muscle loss, maintaining physical strength and function, improving appetite and nutrition, and ultimately enhancing quality of life. Because cachexia involves metabolic changes driven by the underlying disease—such as cancer, heart failure, or chronic lung disease—successful management requires both treating the primary condition and directly addressing the wasting syndrome itself.

Treatment strategies vary depending on the stage of cachexia. In the early stage, called precachexia (when weight loss is less than 5% of body weight), interventions focus on prevention and early nutritional support. Once cachexia is established (with weight loss greater than 5%), more intensive approaches are needed. The most advanced stage, called refractory cachexia, occurs when the underlying disease no longer responds to treatment and life expectancy is typically less than three months; at this point, care focuses on comfort and symptom relief.^[1][16]

Healthcare providers recognize that cachexia differs fundamentally from simple starvation or malnutrition. While increasing food intake helps with starvation, cachexia involves altered metabolism that prevents the body from properly using nutrients. The syndrome triggers ongoing inflammation, increases the body’s energy demands, and causes muscles and fat to break down faster than they can be rebuilt. This means that simply eating more or receiving standard nutritional supplements often cannot reverse the condition on its own.^[1][5]

Current medical guidelines recommend a multidisciplinary approach involving oncologists, nutritionists, physical therapists, and other specialists. Early intervention is considered essential—the sooner treatment begins, the better the potential outcomes. However, many patients and even healthcare providers remain unaware of cachexia, which can delay diagnosis and treatment. Raising awareness about this condition is now recognized as a critical part of improving care.^[8][15]

Standard Treatment Approaches Currently in Use

Traditional management of cachexia has relied primarily on nutritional support and medications to stimulate appetite. Nutritional interventions form the foundation of standard care. Dietitians work with patients to develop meal plans that emphasize high-calorie, high-protein foods. Small, frequent meals throughout the day often work better than three large meals, as many patients with cachexia experience early satiety (feeling full quickly). Protein is particularly important because it provides the building blocks needed to maintain muscle mass.^[6]

Dietary counseling also addresses specific eating challenges. Many patients with cancer cachexia experience taste changes, nausea, difficulty swallowing, or mouth sores from their cancer treatment. Healthcare providers may recommend nutrition supplements, protein shakes, or liquid meal replacements to help patients meet their caloric needs when eating solid food becomes difficult. In some cases, feeding tubes or intravenous nutrition may be considered, though these approaches cannot fully reverse cachexia because the underlying metabolic problems remain.^[6][13]

Medications have traditionally played a limited but important role in managing cachexia symptoms. Corticosteroids (steroid medications) such as dexamethasone and prednisone have been used for decades to stimulate appetite and provide short-term improvements in how patients feel. These drugs work by reducing inflammation and may temporarily increase appetite and energy levels. However, their effects are usually short-lived, typically lasting only a few weeks. More importantly, prolonged use of corticosteroids can actually cause muscle breakdown—the opposite of what patients need—along with other side effects like increased infection risk, high blood sugar, and weakened bones.^[11]

Another medication sometimes used is megestrol acetate, a synthetic hormone that can stimulate appetite. Like steroids, it may help patients feel hungrier and eat more in the short term, but it primarily increases fat tissue rather than muscle mass. Since maintaining muscle is crucial for function and quality of life, this medication addresses only part of the problem. Side effects can include blood clots, fluid retention, and hormonal changes.^[9]

Pain management is another critical component of standard care. Many patients with cachexia experience pain from their underlying disease, which can further reduce appetite and activity levels. Proper pain control with medications allows patients to eat better and potentially engage in physical activity. Similarly, treating other symptoms like nausea, constipation, or depression can indirectly help with cachexia by improving overall function and quality of life.^[6]

Physical activity and exercise, when possible, are increasingly recognized as important parts of standard care. Even light resistance exercises or walking can help preserve muscle mass and strength. Physical therapists can design individualized exercise programs appropriate for each patient’s abilities and limitations. While exercise alone cannot cure cachexia, it works synergistically with nutritional support and medications to help maintain function.^[8]

The major limitation of current standard treatments is that none directly address the root metabolic causes of cachexia. Until recently, there were no medications approved specifically for this condition. This has created a significant unmet medical need, driving researchers to develop and test new therapeutic approaches.^[8][9]

Emerging Treatments Being Tested in Clinical Trials

The landscape of cachexia treatment is changing rapidly as researchers develop drugs that target the specific biological mechanisms driving muscle wasting. Multiple clinical trials are now underway testing innovative approaches, and some have already shown promising results.

One of the most significant recent advances involves a drug called anamorelin hydrochloride. This medication mimics the action of ghrelin, a natural hormone in the body that stimulates appetite and promotes the release of growth hormone. Growth hormone, in turn, helps build and maintain muscle mass. Anamorelin was specifically designed to address cancer cachexia by targeting these pathways. In Phase 3 clinical trials—large studies that compare new treatments to standard care—anamorelin demonstrated the ability to help patients gain lean body mass (muscle) and improve appetite. The drug has been approved for use in Japan for treating cancer cachexia, marking the first regulatory approval specifically for this condition. It represents a major milestone in cachexia treatment research.^[11]

However, anamorelin’s development also illustrates the challenges in treating cachexia. While the drug successfully increased muscle mass and appetite in clinical trials, it did not significantly improve physical function or strength in all studies. This disconnect between gaining muscle mass and gaining functional ability has led researchers to recognize that effective treatment may require addressing multiple aspects of the syndrome simultaneously. Some clinical trials combining anamorelin with exercise programs are exploring whether this integrated approach produces better outcomes.^[8][11]

Another exciting area of research focuses on blocking a protein called GDF-15 (growth differentiation factor 15). Scientists have discovered that levels of GDF-15 are dramatically elevated in many patients with cancer cachexia. This protein acts on a specific receptor in the brain called GFRAL, which controls appetite and metabolism. When GDF-15 binds to GFRAL, it suppresses appetite and may increase metabolism, contributing to weight loss and muscle wasting.

A medication called ponsegromab represents a new class of treatment targeting this pathway. Ponsegromab is a monoclonal antibody—a protein designed to bind to and neutralize GDF-15, preventing it from reaching its receptor in the brain. In a Phase 2 clinical trial published in 2024, ponsegromab demonstrated remarkable benefits for patients with cachexia related to lung, pancreatic, or colorectal cancer. Patients who received the drug gained significantly more weight and showed increased physical activity levels compared to those who received placebo (inactive treatment). Importantly, the weight gain came from both muscle and fat tissue. The drug also appeared quite safe, with minimal side effects—actually safer than some commonly used appetite stimulants.^[10][12]

The clinical trial of ponsegromab was conducted at multiple medical centers across the United States and included 187 participants who had elevated GDF-15 levels. The trial tested whether blocking this protein could reverse cachexia. Results showed that patients receiving ponsegromab gained an average of several pounds over 12 weeks, while those on placebo continued to lose weight. Activity monitors showed that treated patients were walking more and spending more time active. These findings have generated significant excitement in the medical community, and larger Phase 3 trials are now underway to confirm these results.^[10][12]

Researchers are also investigating other biological targets. Some experimental drugs aim to block myostatin, a protein that naturally limits muscle growth. By inhibiting myostatin, these medications might allow muscles to grow larger and stronger. Other approaches target the inflammatory cytokines—chemical messengers like tumor necrosis factor and various interleukins—that drive the metabolic changes in cachexia. Medications that reduce inflammation throughout the body might help slow muscle breakdown.^[1][5]

Some clinical trials are testing whether anabolic hormones can help rebuild muscle. Testosterone and similar hormones naturally promote muscle growth, and researchers are studying whether supplementing these hormones in patients with cachexia can preserve muscle mass. Insulin-like growth factor-1 (IGF-1) is another hormone being investigated for its potential to stimulate muscle protein synthesis.^[1]

Novel combinations of treatments are also being explored. Some trials combine nutritional support with exercise programs and medications, recognizing that attacking cachexia from multiple angles simultaneously may produce better results than any single intervention. For example, providing protein supplements along with resistance exercise and an appetite-stimulating drug might work synergistically to build muscle more effectively than each approach alone.^[8]

Researchers emphasize that they are in the early stages of understanding cachexia at the molecular level. Each clinical trial, whether successful or not, teaches scientists more about which biological pathways are most important to target. The field is experiencing what experts describe as exponential growth, with more researchers, more funding, and more clinical trials than ever before. This increased attention is expected to yield additional treatment options in the coming years.^[8]

Most common treatment methods

• Nutritional interventions
  • High-calorie, high-protein diet plans developed with dietitians to maintain energy and muscle mass
  • Small, frequent meals throughout the day to address early satiety and poor appetite
  • Protein supplements and meal replacement shakes when solid food intake is inadequate
  • Specialized nutrition counseling to address taste changes, swallowing difficulties, and treatment-related eating challenges
  • Feeding tubes or intravenous nutrition in severe cases, though these cannot fully reverse metabolic abnormalities
• Appetite-stimulating medications
  • Corticosteroids (dexamethasone, prednisone) for short-term appetite improvement, though prolonged use can worsen muscle loss
  • Megestrol acetate, a synthetic hormone that increases appetite but primarily adds fat rather than muscle tissue
  • Anamorelin hydrochloride, which mimics ghrelin to stimulate appetite and growth hormone release; approved in Japan for cancer cachexia
• GDF-15 pathway inhibitors
  • Ponsegromab, a monoclonal antibody that blocks GDF-15 protein, tested in Phase 2 trials showing weight gain and increased physical activity in patients with lung, pancreatic, or colorectal cancer cachexia
  • Other experimental drugs targeting the GDF-15/GFRAL receptor pathway in the brain that controls appetite and metabolism
• Exercise and physical rehabilitation
  • Resistance training and light exercise programs designed by physical therapists to preserve muscle mass and strength
  • Combination approaches pairing exercise with nutritional support and medications for synergistic benefits
  • Activity modifications appropriate for individual patient abilities and limitations
• Symptom management approaches
  • Pain control medications to improve appetite and enable physical activity
  • Treatment of nausea, constipation, depression, and other symptoms that interfere with eating and function
  • Management of the underlying disease (cancer, heart failure, etc.) to reduce inflammatory drivers of cachexia
• Experimental biological therapies
  • Myostatin inhibitors being tested to remove natural brakes on muscle growth
  • Anti-inflammatory medications targeting cytokines that drive metabolic changes and muscle breakdown
  • Anabolic hormone supplementation with testosterone or insulin-like growth factor-1 to promote muscle protein synthesis
  • Combination therapies addressing multiple pathways simultaneously in clinical trial settings